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ess: a122@mail.ncku.edSummary Sublingual immunotherapy (SLIT) has been recommended as a viable
alternative to subcutaneous injection therapy in the treatment of airway allergies,
though more data is needed from well-controlled studies for documenting its
efficacy in different ethnic populations. Ninety-seven children (age range 6–12
years), mild-to-moderate asthma with a single sensitization to mite allergen, were
enrolled from 5 medical centers in Taiwan to evaluate the efficacy and safety of SLIT
with standardized mite extracts, which contain Dermatophagoides pteronyssinus
(D.p.) and Dermatophagoides farinae (D.f.). Patients were double blinded and
randomly assigned to either a SLIT or placebo group. Following 24 weeks of study
period, symptom and medication scores, lung function tests, skin prick tests, total
serum IgE, and specific IgE to D.p. and D.f. were recorded. The results showed that
there was statistically significant difference between these two groups in the
analysis of daily (P ¼ 0:011), nighttime (P ¼ 0:028), and daytime (P ¼ 0:009)
asthmatic scores after 24 weeks of treatment. Patients receiving SLIT improved
their forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), and peakElsevier Ltd. All rights reserved.
2353535; fax: +886 6 2753083.
u.tw (J.-Y. Wang).
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Sublingual immunotherapy in mite-sensitive asthmatic children 1375expiratory flow (PEF) as compared to baseline (P ¼ 0:042, P ¼ 0:048, and P ¼ 0:001,
respectively). No differences were found in skin prick test, total serum IgE and
specific IgE to D.p. and D.f. Tolerance with high-dose SLITwas good with few minor
adverse events reported. Our results indicated that a 24-week SLIT is of clinical
benefit to mite-sensitive asthmatic children in Taiwan.
& 2005 Elsevier Ltd. All rights reserved.Introduction
The use of sublingual immunotherapy (SLIT) to
treat allergic airway diseases has increased over
the past few decades and its effectiveness has been
demonstrated in several clinical trials, though some
of the early studies tended to be small scale and
had methodological flaws.1 In 1998, the WHO has
recommended SLIT as a suitable treatment for
allergic rhinoconjunctivitis in adults based on six
double-blind, placebo-controlled studies.2–7 Two of
the studies were carried out in children, with
systemic side effects being reported in one.4 It was
concluded that more studies were needed before
SLIT could be recommended for general use in
children as an alternative to subcutaneous immu-
notherapy. In 2001, Rakoski et al.8 reviewed 20
published studies on SLIT, eighteen of which were
performed in patients with rhinitis,2–19 and two in
patients with asthma.20,21 Controversy still remains
over the use of SLIT in children with asthma.
Although recently, there are several studies
focused on the SLIT on grass pollen allergic
children,22–24 only four double-blind placebo-
controlled trials have focused on asthmatic chil-
dren sensitive to house dust mites (HDM).5,20,21,25
Two of them showed improvement in symptoms
and drug scores with few minor side effects.20,21
The other two comparable studies did not sub-
stantiate the clinical efficacy of SLIT, though they
reported the safety and tolerance of SLIT to be
promising.5,25
Although SLIT appears to be effective to a degree
and relatively safe, current evidence indicates the
needs in defining the route of administration
(sublingual-swallow vs. sublingual-spit), the dura-
tion of treatment, the optimal dose of standardized
allergen extracts, and most importantly in the
different ethnic population for the global applica-
tion. Therefore, to know the efficacy and safety of
this new therapy of SLIT in mite-sensitive asthmatic
children is important before its wide application of
treating allergic asthma in children. As far as we
know, there have been no reports in Asian
countries. In the present study, we have applied
high doses of mite allergens as final accumulated
doses over 500 times higher than those given insubcutaneous immunotherapy, in a relatively short
time. Our primary aim is to evaluate the efficacy of
SLIT with StaloralTM, the standardized combined
HDM extracts, Dermatophagoides pteronyssinus
(D.p.) and Dermatophagoides farinae (D.f.), in
asthmatic children sensitized to HDM. Secondary
objective is to evaluate the safety and tolerability
of this SLIT in our asthmatic children.Materials and methods
Patients
Asthmatic children, aged 6–12 years with at least 1-
year history of mildly persistent to moderately
persistent (GINA—global initiative for asthma, step
2–3), were enrolled in this study. They were allergic
to HDM only. The diagnosis of a single allergy HDM
(D.p.) and (D.f.) was based on clinical history,
positive skin tests using standardized extracts
(Stallergenes SA, Antony, France), and the pre-
sence of specific IgE against mites as shown in MAST
with or over class 3+as the cutoff value. Patients
were excluded if they were sensitive to either
cockroach, Alternaria, Cladosporium, dog, cat
danders, or pollens, by skin prick tests (wheal
X5mm), or has allergen-specific IgE antibodies
(X1+, tested by MAST CLA allergen test, Hitachi
chemical Diagnostics, Inc. (CA, USA) against above
allergens. Children were enrolled in this study
only if their forced expiratory volume in 1 s (FEV1)
were greater than 70% of that predicted, and
the reversible peak expiratory flow (PEF) rate
exceeded 15% after inhalation of b2-agonists.
Patients who had previously been treated with
immunotherapy, oral or parenteral corticosteroids
for more than 15 consecutive days, depot steroids,
inhaled corticosteroids in doses greater than
1000 mg/day (beclomethasone dipropionate), in-
haled b2-agonists more than four times/day,
and those suffering from other respiratory diseases
that were not suitable for immunotherapy, such
as anatomical abnormality of upper respiratory
tract, and congenital cardiovascular diseases, were
excluded.
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hundred and ten study subjects were randomly
assigned to receive either SLIT (56 patients) or
placebo therapy (54 patients). Informed consent
was obtained from all participant subjects by their
respective guardians. Intention-to-treat analysis
was carried out. The human ethical and clinical
trial committee in each study center has approved
this trial.Study design
This double-blind, randomized, placebo-controlled
study was undertaken to evaluate the efficacy and
safety using StaloralTM (Stallergenes SA, Antony,
France) as a standardized combined extracts of
HDM—D.p. (50%) and D.f. (50%), for sublingual use
in asthmatic children sensitized to HDM. The study
took 30 weeks, including 2 weeks of evaluation for
enrollment criteria (visit V0), 2 weeks for collecting
baseline data (visit V1), 3 weeks of induction
therapy (visits V2–V4), 21 weeks of maintenance
therapy (visits V5–V15), and 2 weeks of follow-up
evaluation (visit V16), and was conducted in five
medical centers throughout Taiwan Island.Treatment
After 2-week screening and 2-week baseline data
collection, all eligible patients were randomly
assigned to one of two groups; A, those receiving
increasing higher doses of SLIT (the even mixture of
allergenic extracts of D.p. and D.f.) or B, those
receiving the placebo, followed by maintenance
therapy. The SLIT mite extracts had three concen-
trations: 10, 100, and 300 IR/mL according to
manufacturer’s in vivo standardization, i.e. an
allergen extract is attributed a value of 100 IR/mL
when it induces a mean 7mm wheal in a skin prick
test in 30 subjects sensitized to the allergen in
question. The extract and placebo were dispensed
in the same glycerosaline diluentes. During the first
3-week induction period, patients received increas-
ing higher doses, starting with one drop from the
10 IR/mL (blue vial) and increasing to 10 drops on
day seven, taken sublingually in the morning before
breakfast. The drops were kept in the mouth for at
least 2min and then swallowed. Patients started to
take one drop from from 100 IR/mL vial (red vial)
on day 8 and the dose was increased to 20 drops on
day 14. On day 15, the patients were started on 7
drops from the 300 IR/mL vial (gray vial) and were
given an increasing number of drops to 20 drops on
day 19. Once the 20-drop 300 IR/mL was reached,
the patients were maintained on this dose foranother 21 weeks. The cumulative dose was about
41824 IR, which was equivalent to 1.7mg D.p. and
3.0mg D.f.Diary card
The patients’ parents were provided with diary
cards on which they recorded asthmatic scores,
medication consumption, and peak expiratory flow
rate (PEFR) throughout the run-in and treatment
periods. Daytime and nighttime asthma symptoms
were recorded on a four-point scale (0 ¼ no
symptom, 1 ¼ mild, 2 ¼ moderate, 3 ¼ severe
symptoms). Scores of daytime symptoms plus that
of nighttime made up the daily asthma scores.
During the trial, patients were allowed to take the
following rescue medications if needed: inhaled
corticosteroids (budesonide turbuhaler), inhaled
b2-agonist (terbutaline aerosol), and oral corticos-
teroids (prednisolone 5mg). The number of puffs
and/or tablets was recorded. Daily measurements
of PEFR were made in the morning and night, three
measurements were recorded on each occasion and
the best was used in subsequent calculations.Lung function test
Forced vital capacity (FVC), FEV1, forced expira-
tory volume between 25% and 75% of vital capacity
(FEF25–75), and PEF were measured using spiro-
metry by the physician at the visits V0, V1, V2, V15,
and V16.Skin prick test
At the visits V0 and V15, the skin prick test was
performed on the forearm with the standardized
allergen panel (Stallergenes, France) for D.p. and
D.f., cockroach, cat, and dog dander, Alternaria,
Cladosporium, and pollen mixture extracts. A mean
diameter X5mm and over 50% of the diameter of
the wheal with positive control (histamine phos-
phate 9%) was considered positive.Total serum IgE and specific IgE to D.p. and
D.f.
At visits V0 and V15, total IgE and specific IgE levels
against D.p., and D.f. in the study subject were
measured by turbidimetry, and by MAST CLA Allergy
Test (Hitachi Chemical Diagnostics, Inc., CA, USA),
respectively. Results were expressed in interna-
tional units per milliliters (I U/mL).
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Before and after 24 weeks of therapy patients were
interviewed and physically examined by an attend-
ing physician without previous knowledge of pa-
tient treatments. The physician was required to
assess changes in asthmatic scores, drug consump-
tion, and lung function test from the baseline.Assessment of safety
All adverse events were recorded. Physical exam-
ination, vital signs, and physician’s global assess-
ment of tolerability for patients were evaluated.
Safety laboratory procedures, including hematol-
ogy, biochemistry, and urinalysis were also carried
out for screening. Global assessment of tolerability
of the patients was recorded by the physician and
scored from 1 to 4 (1 ¼ good, 2 ¼ satisfactory,
3 ¼ not satisfactory, and 4 ¼ bad).Statistical methods
Two-way analysis of variance (ANOVA) with fixed
factor treatment, center, and treatment-by-center
interaction as terms in the model for continuous
variable was used to compare among treatment
groups. The treatment-by-center interaction is
considered statistically significant if the P value
for the interaction was smaller than 0.10. The
paired t-test was used to test changes from
baseline within each treatment group. Cochran–
Mantel–Haenszel statistics for center control for
categorical variables was used to compare differ-
ence among treatment groups.Results
Patients
Out of 145 asthmatic patients screened, 110 were
randomly assigned to receive either SLIT (56
patients) or placebo (54 patients). Thirteen pa-
tients, seven from SLIT group and six from placebo
group, withdrawn or terminated early from
the study due to lack of direct efficacy (N ¼ 3, 3
in SLIT group), loss of follow-up (N ¼ 8, 3 in SLIT
group, 5 in placebo group), or withdrawn consent
(N ¼ 2, 1 in each group). Ninety-seven patients,
49 in SLIT and 48 in placebo group, completed
the study and were eligible for analysis. Demo-
graphic data of the patients are summarized in
Table 1.Symptom scores
There was statistically significant difference be-
tween the two groups in the analysis of daily
(P ¼ 0:011), nighttime (P ¼ 0:028), and daytime
(P ¼ 0:009) asthmatic scores after 24 weeks of
treatment (Figs. 1A–C). Improvement of asthma
symptoms took place gradually over time in the
SLIT group. Patients in the placebo group had
almost the same asthma score at the endpoint as
they had at baseline (Fig. 2).Medication scores
The use of oral corticosteroids was reduced in with
SLIT (0.0870.42), though the reduction was not
statistically significant (P ¼ 0:183) (Fig. 3). The use
of antihistamines at week 24 was gradually reduced
in SLIT treated group (0.0970.46) whereas it
was increased in the placebo group (0.0570.46)
(Table 2).Peak expiratory flow (PEF)
Compared to baseline, patients treated with SLIT
had increased morning and night PEF (10.9+40.0
and 11.1+41.6 L/min, respectively), though the
increases were not statistically meaningful
(P ¼ 0:072 in morning PEF and P ¼ 0:070 in night
PEF).Lung function test
Endpoint FVC, FEV1, and PEF was found to be
significantly increased in the SLIT group (P ¼ 0:042,
0.048, and 0.001, respectively). On the other hand,
the within-group analysis failed to demonstrate
any significant improvement of FVC, FEV1, and
PEF in the placebo (P ¼ 0:584, 0.977, and
0.075, respectively) (Figs. 4A–C). However, there
was no statistically significant between-group
difference.Skin prick test
At the end of treatment, skin sensitivity to D.p. And
D.f. was greatly improved in both groups and
considerable numbers of patients responded nega-
tively to the skin prick test with D.p., accounted
57% (28/49) in SLIT group and 32% (15/48) in
placebo group, and with D.f., 53% (26/49) in SLIT
group and 36% (17/48) in placebo group.
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Table 1 Demographic and baseline characteristics of study population.
Characteristics SLIT Placebo P-value
Gender 0.864y
N 49 48
Male 30 (61%) 28 (58%)
Female 19 (39%) 20 (42%)
Age (yr) 0.450y
Mean7SD 7.971.6 8.271.7
Median 8.0 8.0
Range 5.0–11.0 5.0–12.0
95% CI 7.5–8.3 7.7–8.7
Weight (kg) 0.745y
Mean7SD 30.578.1 31.078.8
Median 28.8 31.0
Range 18.5–52.0 17.6–59.0
95% CI 28.3–32.6 28.5–33.5
Height (cm) 0.606y
Mean7SD 130.078.6 131.4711.5
Median 130.5 131.0
Range 112.0–144.1 110.7–154.0
95% CI 127.7–132.3 128.2–134.7
Severity of asthma 0.272
Intermittent asthma 0 (0%) 0 (0%)
Mild persistent asthma 36 (73%) 33 (69%)
Moderate persistent asthma 13 (27%) 15 (31%)
Severe persistent asthma 0 (0%) 0 (0%)
PEFR reversibilityz (%) 0.190y
Mean7SD 50.8738.6 48.7742.5
Median 35.0 28.0
Range 15.0–178.0 5.0–194.0
95% CI 38.9–62.7 35.3–62.1
Cochran–Mantel–Haenszel statistics with center control.
yTwo-way ANOVA with treatment, center, and treatment-by-center-interaction.
zReversibility of PEFR after b2-agaonists inhalation.
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Between-groups analysis demonstrated no group
difference in change of total serum IgE at the end
of treatment (P ¼ 0:063). At the end of treatment,
the levels of specific IgE to D.p. and D.f. remained
almost the same as the baseline levels in both
groups (Table 3).Global assessment of asthmatic symptoms by
patient and by physician
After 24 weeks of treatment, 40 out of 49 subjects
(81.6%) in SLIT group expressed that they felt their
asthmatic symptoms had improved. A considerable
numbers of patients in SLIT group improved
severity of asthma from ‘‘persistent’’ to ‘‘inter-mittent’’ (N ¼ 26, 52%). It showed statistically
significant (P ¼ 0:043) compared to the placebo
group (Table 4).Safety and tolerability assessment
There was no incidence of serious drug-related
adverse events reported. Between-group differ-
ences in all adverse events (6 in SLIT vs. 7 in
placebo, P ¼ 0:861), drug-related adverse events
(5 in SLIT vs. 3 in placebo, P ¼ 0:487), and serious
events (1 in SLIT vs. 4 in placebo, P ¼ 0:129) were
not significant different. Treatment with SLIT or
placebo was tolerable to most patients, most of
whom marked ‘‘Satisfactory’’ or ‘‘Good’’ when
evaluated by physician.
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Figure 1 Comparison of asthma scores (Mean7SD) (A,
daily; B, nighttime; C, daytime) before and after 24-
week treatment between SLIT and placebo group.
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Figure 2 Changes of daily asthma scores (Mean7SD) in
SLIT and placebo groups throughout the study period.
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Figure 3 Comparison of change of oral corticosteroids
use in the two groups throughout the treatment course.
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In this multi-center, double-blind, placebo-controlled
study, we assessed the efficacy and safety of SLITwith
D.p. and D.f. extracts as compared with those of
placebo therapy in asthmatic children. This study can
be distinguished from others reports on SLIT with
regard to its larger patient number, maximal daily
dose, high cumulative dose, rush style, and admini-
strated in different ethnic population.
The mean daily asthma score in the SLIT group
decreased progressively and demonstrated signifi-
cant difference in comparison with the placebo
group over the 6-month treatment program. Since
reduction in symptoms is the most convincing
parameter indicating efficacy and it is critical to
document a statistically significant difference
between the active group and the placebo group,
the clinical efficacy of this is very encouraging.
Significant declines in asthma score were also
observed in three studies with the duration of
treatments 18 months, 2 years, and 2 years,
respectively.4,20,21 Documentation about the clin-
ical efficacy of sublingual immunotherapy is influ-
enced by the amount of allergen extract
administrated, the duration of the treatment, and
criteria for concluding as efficacy. Our positive
outcome could be best explained by our high-dose
regimens. A longer duration of treatment might
further improve the clinical efficacy. A study by
Bahceciler et al.25 reported a significant decrease
in daily asthma score over a 6-month treatment
period. The number of patients (n ¼ 15) in that
study, however, was limited.
The use of oral corticosteroids was reduced in
the SLIT group, the gradually decreasing pattern
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Figure 4 (A) mean FVC; (B) mean FEV1; (C) mean PEF
before treatment (W0) at the end of treatment (W24), and
2 weeks after treatment (W26) in patients of SLIT and
placebo groups.
Table 3 Comparison of total serum IgE, specific IgE to D
SLIT Plac
Baseline Week 24 Change Base
Total IgE (I U/mL)
Mean7SD 829.87582.0 959.57778.5 129.77460.6 780.
P-value 0.057
Specific IgE D. p.
Mean7SD 3.9070.37 3.9270.28 0.0270.32 3.9
P-value 0.659
Specific IgE D.f.
Mean7SD 3.9270.34 3.9470.32 0.0270.38 3.8
P-value 0.710
Paired t-test.
yTreatment effect by two-way ANOVA with treatment, center,
Sublingual immunotherapy in mite-sensitive asthmatic children 1381correlated well with symptom scores. Although the
reduction was not statistically significant
(P ¼ 0:183). In order to compare with previous
trials of allergic disease, we used an arbitrary
scoring system to estimate concomitant drug
consumption. Although it is difficult for different
drugs to derive a general numeric score system,
establishment of an acceptable and realistic way of
assessment for medication score is needed in the
future. Bousquet et al.20 noted a significant
reduction in inhaled corticosteroids, and both
Pajno et al.20 and Bahceciler et al.21 observed
reduction in rescue medications used. The con-
sumption of antihistamine, most commonly used
for allergic rhinoconjunctivitis, decreased progres-
sively in our SLIT group, but not in the placebo
group. SLIT has been shown to reduce nasal
symptoms and drug consumption in several studies
that have made use of allergen extracts, including
grass pollen,2,3 HDM,4–6 and Parietaria.7 Studies
comparing effectiveness of SLITon different sites of
allergic airway are still lacking.
According to GINA guideline, grading of asthma
severity is not based on clinical symptoms only but
also on objective parameters of lung function test.
Measurement of FEV1 and PEF thus is at least as
important as symptom score in assessment of
clinical efficacy. At the end of the study, SLIT was
observed to be beneficial, within group, with
significant changes in several parameters of lung
function test, including FVC, FEV1, and PEF, though
the duration of treatment were not long enough to
see between-group difference. In Bahceciler’s
study,22 which had the same treatment period,
there was no such within group differences
about PEF, possibly because of the relatively lower
dosing used in that study. In all, significant
reduction of symptom scores between two groups.p. and D.f. between SLIT and placebo.
ebo Group difference
line Week 24 Change Baseline Change
67592.0 695.57525.1 85.1759.8
0.221 0.671y 0.063y
270.35 3.7570.81 0.1770.88
0.197 0.695y 0.169y
870.67 3.8570.58 0.0270.91
0.875 0.708y 0.686y
and treatment-by-center-interaction.
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Table 4 Asthma severity at week 24 versus baseline between SLIT and placebo.
Asthma severity SLIT Placebo Group difference
Baseline Week 24 Baseline Week 24 Change from
baseline
Intermittent 0 (0%) 26 (53%) 0 (0%) 19 (40%)
Mild/moderate 49 (100%) 23 (47%) 48 (100%) 29 (60%)
P-value 0.043
Cochran–Mantel–Haenszel statistics with center control.
C.-K. Niu et al.1382and within-group improvement of lung function
test are most encouraging and convincing evidence
in this study for efficacy of SLIT in asthmatic
children.
On the contrary, systemic immunologic effects of
SLIT were not changed during this 6-month trial
period. Neither total IgE nor specific IgE showed
any significant change or between-group differ-
ence. Surprisingly, certain percentages of asth-
matic children, both in SLIT and placebo groups,
showed a reduction in reactivity in the skin prick
test. Decreased skin reactivity may be explained by
several factors including environment control or
medication use. Immune-mediated reaction was
unclear in our study, as it was in Bahceciler’s
study.25 Another similar study also failed to
demonstrate significant change of total IgE and/or
specific IgE even after 2-year treatment.21 In
Bousquet’s study,20 specific IgE and IgG4 increased
significantly in SLIT group and decreased in placebo
group during 2-year treatment period.
Since SLIT is regarded as much safer than other
forms of immunotherapy, its efficacy can be
ascribed to a higher dose than traditional immu-
notherapy. The cumulative doses in SLIT have been
between 20 and 375 times the doses given in
subcutaneous immunotherapy.26 This study adopted
much higher doses in a rush schedule to determine
whether there are any dose-related effects and/or
systemic reactions. In the end, there were only few
mild-to-moderate local reactions such as tongue
disorder, vomiting, abdominal pain, and circumoral
parethesia in SLIT group (5 patients, 10 inci-
dences). Although urticaria and gastrointestinal
symptoms were reported in Tari’s trial in early
1990,4 we have not found a single serious adverse
drug-related event throughout the course of treat-
ment. No severe side effects have been reported
during past few years. With the record-high
cumulative dose in the present study, the safety
of SLIT seems universally promising, though cost
effectiveness needs further study.
In conclusion, SLIT at ultrahigh doses admini-
strated in a rushed schedule to asthmatic childrenshowed clinical efficacy and safety. Future studies
are needed to further evaluate immunologic
mechanism and cost effectiveness of SLIT before
it can be used as an alternative to subcutaneous
immunotherapy in children.References
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